Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche

by Vandana Singh, Benzinga Editor

June 16, 2021 9:26 AM | 1 min read |

Atea Pharmaceuticals Inc AVIR has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license agreement with Roche Holding AG RHHBY of $50 million.
Under the license agreement, Roche and Atea are jointly developing AT-527 for the treatment of COVID-19.
Atea retains rights to commercialize AT-527 in the U.S., and Roche has the exclusive right to commercialize AT-527 outside of the U.S.
AT-527 is an orally administered, direct-acting antiviral developmental agent in Phase 3 development to treat COVID-19.
In April, the first patient was dosed in the Phase 3 MORNINGSKY trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting.
Price Action: AVIR shares closed at $23.85 on Tuesday.

Posted In: Biotech News Health Care Contracts Small Cap General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.